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INTRODUCTION
Cyclooxygenase (also be known as prostaglandin endoper-
oxidase or prostaglandin G/H synthase) is the rate-limiting
enzyme for the production of prostaglandins (PGs) and throm-
boxanes from free arachidonic acid (1), which is liberated
from the membrane-bound phospholipids when the cell is
injured or there is receptor activation. Two isoforms of cyclo-
oxygenase (COX) have been identified, COX-1 and COX-2
(2-4). COX-1 is believed to be responsible for the synthesis
of prostaglandins during homeostasis and it is constitutively
expressed at low levels (5). In contrast, the COX-2 gene is
an immediate-early response gene that is inducible by many
stimuli (1, 6). 
Caveolins (Cav) are integral membrane proteins present
in the caveola, the small flask-shaped and detergent insolu-
ble invaginations in the plasma membrane, and they have
been implicated to function in the vesicular transport pro-
cesses and for the transduction of receptor generated signals
(7). Recent studies have shown that many signal proteins,
enzymes and receptors are localized in the caveolae by being
anchored there through the caveolins (8). In 2001, Liou and
coworkers (9) have reported that COX-2 was co-localized
with Cav-1 in human fibroblasts. In addition, we have report-
ed COX-1 was also co-localized with Cav-1 and Cav-2 in
human embryonic kidney (HEK 293) cells (10). Many inves-
tigators have reported that Cav-1 and Cav-2 bind to some
proteins and regulate their functions. With respect to Cav-3,
there is a little information on the protein-protein interac-
tion of Cav-3. Cav-3 was shown to be specifically expressed
in muscle and it was also detected in brain astroglial cells
(11). In 1999, Schwab and co-workers (12) reported that rat
chondrocytes cultured from the femoral and tibial articular
surfaces of knee joints of newborn rat also expressed Cav-3.
COX-2 has been related with inflammation that was induced
by many causes. COX-2 inhibitors have used to decrease the
pain of arthritis patients. In this connection, we hypothesize
that Cav-3 may also be related with the function of COX-2.
The purpose of this study, was to investigate the cellular
localization of the inducible form of COX-2 and Cav-3 in
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Evidence for Cyclooxygenase-2 Association with Caveolin-3 in Primary
Cultured Rat Chondrocytes
The purpose of this study was to demonstrate the cellular localization of cyclooxy-
genase-2 (COX-2) and caveolin-3 (Cav-3) in primarily cultured rat chondrocytes.
In normal rat chondrocytes, we observed relatively high levels of Cav-3 and a very
low level of COX-2 mRNA and protein. Upon treating the chondrocytes with 5  M
of CdCl2 (Cd) for 6 hr, the expressions of COX-2 mRNA and protein were increased
with the decreased Cav-3 mRNA and protein expressions. The detergent insolu-
ble caveolae-rich membranous fractions that were isolated from the rat chondro-
cytes and treated with Cd contained the both proteins of both COX-2 and Cav-3 in
a same fraction. The immuno-precipitation experiments showed complex forma-
tion between the COX-2 and Cav-3 in the rat chondrocytes. Purified COX-2 with
glutathione S-transferase-fused COX-2 also showed complex formation with Cav-3.
Confocal and electron microscopy also demonstrated the co-localization of COX-2
and Cav-3 in the plasma membrane. The results from our current study show that
COX-2 and Cav-3 are co-localized in the caveolae of the plasma membrane, and
they form a protein-protein complex. The co-localization of COX-2 with Cav-3 in
the caveolae suggests that the caveolins might play an important role for regulat-
ing the function of COX-2.
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cultured rat chondrocytes as a first step to demonstrating the
relationship between COX-2 and Cav-3. 
MATERIALS AND METHODS
Cell culture and identification of rat chondrocytes
Cartilage of normal appearance was aseptically prepared
from the femoral and tibial articular surfaces of knee joints
of newborn rats. Catilage pieces were digested enzymatically
according to the slightly modified method of Kiepe (13).
Briefly, hyaluronidase (0.5%), trypsin (0.25%) and collage-
nase (0.2%) were treated for 2 hr. After washing and centrifu-
gation, cells were resuspended in Ham’s F12/Dulbecco’s
Modified Eagle’s Medium with 10% fetal bovine serum, 50
g/mL gentamicin. The cells were grown at 37℃ with 5%
CO2 in air. In order to identify chondrocytes, the expression of
type II collagen and aggrecan mRNAs and proteins as a chon-
drogenic markers were determined by RT-PCR and Western
blot analysis. For cell culture, used chemicals and reagents
were purchased from Gibco BRL (Grand Island, NY, U.S.A.)
and Sigma-Aldrich (St. Louis, MO, U.S.A.). Used primer
sequences (TaKaRa Korea Biomedical Co., Seoul, Korea) are
shown in Table 1.
Glutathione S-Transferase (GST)-COX-2 and -Caveolin-3
fusion protein
For purification of the GST-COX-2 and -Cav-3 fusion pro-
tein, the coding region of COX-2 and Cav-1 cDNA were
amplified by polymerase chain reaction and cloned into SalI
and NotI sites for COX-2 and BamHI and EcoRI sites for Cav-
1 of the GST expression vector pGEX4T-3 and -1, respec-
tively. The GST fusion proteins were expressed in transformed
Escherichia coli induced by isopropyl-1-thio- -D-galactopy-
ranoside and purified by affinity chromatography using GST
purification modules (Amersham Pharmacia Biotech, Birk-
inghamshire, U.K.). Immunoprecipitation experiments using
respective antibodies were performed using modified method
of the previous report (9).
Isolation of total RNA and RT-PCR analysis
Total RNA was extracted with TRI Reagent (Sigma-
Aldrich) according to the manufacturer’s instructions and
500 ng total RNA was reverse transcribed with 5 U of AMV
reverse transcriptase XL for 30 min. The cDNAs were used
as templates for PCR and the conditions for the PCR were
as follows; one cycle of 1 min at 94℃, 35 cycles each for 30
sec at 94℃, 30 sec at 55℃ and 90 sec at 72℃, and a final
cycle of 10 min at 72℃. The products (15  L) were sepa-
rated by a 1% agarose gel electrophoresis and stained with
ethidium bromide. Used reagents for RT-PCR were bought
from TaKaRa.
Western blot analysis
The primarily cultured rat chondrocytes were washed with
cold phosphate-buffered saline (PBS, pH 7.4), harvested and
homogenized in 9 volumes of 0.3 M sucrose, 0.26 unit/mL
aprotinin, 0.1 mM phenylmethylsulfonyl fluoride, 10  g/mL
leupeptin and 10  g/mL trypsin inhibitor, with 10 strokes
of a motor-driven Teflon/glass homogenizer. The homogenate
was centrifuged for 10 min at 8,000 rpm, and the supernatant
centrifuged for 20 min at 8,000 rpm. The supernatant was
centrifuged for 40 min at 45,000 rpm, and the membrane
pellet was re-suspended in 0.25 M sucrose, 100 mM KCl, 5
mM MgCl2, and 50 mM Tris (pH 7.4). Aliquots were heat-
ed at 100℃ for 10 min in sample buffer and subjected to
10% SDS-polyacrylamide gel electrophoresis. The separated
proteins were transferred electrophoretically to a Hybond-P
polyvinylidene difluoride transfer membrane (Amersham
Pharmacia Biotech). This was blocked with 5% non-fat dried
milk and incubated with polyclonal goat anti-human COX-2
antibody (1:500, Santa Cruz Biotechn, Santa Cruz, CA, U.S.A.)
or monoclonal mouse anti-rat Cav-3 antibody (1:200, Trans-
duction Lab., Lexington, MS, U.S.A.), polyclonal rabbit anti-
mouse aggrecan (1:1,000, CHEMICON, Temecula, CA,
U.S.A.) or monoclonal mouse anti-human collagen type 2
(1:1,000, CHEMICON) for 1 hr at room temperature fol-
lowed by horseradish peroxidase-conjugated secondary anti-
bodies (1: 3,000, Jackson Immunoresearch, West Grove, PA,
U.S.A.) for 1 hr at room temperature. After washing, the
membrane was visualized by the ECL kit (Amersham Phar-
macia Biotech).
Preparation of caveolae-enriched membrane fractionation
Caveolae-rich membrane fractions from the Cd (5  M for
6 hr)-treated rat chondrocytes were fractionated using mod-
ified sucrose gradient ultracentrifugation (9, 14). In brief,
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mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 10  g/mL leupeptin, 10  g/
mL trypsin inhibitor, and 60 mM OG, octyl  -D-glucopy-
ranoside, Sigma-Aldrich) followed by sonication. The homo-
genate was brought to 40% sucrose by addition of an equal
volume of 80% sucrose and loaded in an ultracentrifuge tube.
A discontinuous sucrose gradient was layered on top of the
sample by placing 4 mL of 30% and 4 mL of 5% sucrose,
respectively. After centrifugation at 200,000×g for 16-20
hr at 4℃, the twelve 1-ml fractions from the top to the
bottom were collected. Each fraction was analyzed by West-
ern blot for its COX-2 and Cav-3 using specific antibodies,
respectively. 
Immuno-precipitation of COX-2 and Caveolin-3
The lysates of Cd-treated rat chondrocytes were incubated
with antibodies specific for Cav-3, COX-2 or a pre-immune
control IgG at a final concentration of 4  g/mL for 4 hr at 4
℃. Protein-A-Sepharose was then added for 2 hr at 4℃.
Thereafter, the samples were centrifuged and the pellets were
washed 4 times with PIPA buffer (150 mM NaCl, 1 mM
EDTA, 60 mM OG, 1% NP-40, 0.05% SDS, and 10 mM
Tris; pH 8.0) and then prepared for the Western blotting
analysis by boiling in the sample buffer to determine whether
interactive binding has occurred between COX-2 and Cav-3.
Confocal microscopy
The cultured rat chondrocytes on cover slips were fixed
with 95% ice-cold ethanol for 10 min at room temperature
and permeabilized by 0.1% Triton X-100 solution in PBS
(10 min, room temperature). The nonspecific binding sites
were blocked with 10% goat serum in PBS for 30 min in
room temperature. Polyclonal COX-2 antibody (1:200) and
monoclonal Cav-3 antibody (1:50) were treated to the fixed
cells for 1 hr in room temperature. Secondary antibodies with-
out prior antibody treatment were also included as controls.
After washing, cells were double stained with FITC- and
Texas Red-conjugated secondary antibodies for 30 min. After
washing, samples were examined at the appropriate wave-
lengths under a Bio-Rad MRC 1000 confocal microscope
(Hercules, CA, U.S.A.). More than 50 cells have been inspect-
ed per experiment and the photos of cells with typical mor-
phology and staining are presented.
Electron microscopy (EM)
For the immunogold EM study of Cd-treated rat chondro-
cytes, cells that had been grown on a culture dish were rinsed
with PBS followed by fixation in PBS containing 0.1% glu-
taraldehyde, 4% paraformaldehyde and 3.5% sucrose for 1
hr at 4℃. The cells were then scraped from the culture dish
and centrifuged to obtain the cell pellet that was later embed-
ded in 1% agar in PBS. The cell blocks were then washed
three times in PBS followed by postfixation with 1% osmi-
um tetroxide on ice for 2 hr, washed three times, and stained
the block with 0.5% uranyl acetate, all in PBS. The cells
were then embedded in Epon 812 after dehydration in an
ethanol series. Ultrathin sections were collected on Formvar/
carbon-coated nickel grids, which were then floated on drops
of freshly prepared 3% sodium metaperiodate for 30 min.
The immunogold labeling procedure was modified from
Spector et al. (15). After etching and washing, the grids were
placed on 50- L droplets of solution A (phosphate saline solu-
tion, pH 8.2, containing 4% normal goat serum, 1% bovine
serum albumin, 0.1% Tween 20, 0.1% sodium azide) for
30 min. Grids were then incubated for 2 hr at room temper-
ature in a humidified chamber on 50- L droplets of the anti-
human COX-2 and anti-rat Cav-3 antibodies appropriately
diluted in solution B (solution A but with 1% normal goat
serum) followed by rinses in solution B. The grids were react-
ed with the 10-nm gold-conjugated goat anti-mouse IgG
or 15-nm gold-conjugated rabbit anti-goat IgG diluted in
solution A. After washes in PBS and deionized water, the
grids were stained with uranyl acetate (7 min) and lead cit-
rate (2 min) and were viewed with a Hitachi H-7100 (Tokyo,
Japan) electron microscope. 
RESULTS
Rat chondrocytes culture and identification
As the first step of the current study, we have character-
ized primarily cultured rat chondrocytes by using RT-PCR
and Western blot analysis with employing type II collagen
and aggrecan as the chondrogenic markers. Fig. 1A shows
the light microscopic morphology of the primarily cultured
rat chondrocytes. Fig. 1B, C shows the mRNA and protein
expression of the chondrogenic marker. From these results,
the cells used in the current study had the characteristics of
chondrocytes.
Expression of COX-2 and Caveolin-3 in the normal or Cd-
treated rat chondrocytes
We examined the expressions of COX-2 and Cav-3 mRNAs
and proteins in the normal or Cd-treated rat chondrocytes.
The results shown in Fig. 2 indicate that the expressions of
Cav-3 mRNA and protein were observed in the un-stimu-
lated rat chondrocytes. In the un-stimulated rat chondrocytes,
the level of COX-2 mRNA and the protein expression were
very weakly detected (Fig. 2). However, when the rat chon-
drocytes were stimulated with Cd (5  M) for 6 hr, the expres-
sion of COX-2 mRNA and protein markedly increased to
the maximal level in a dose- and time-dependent manner
(data not shown). The expressions of Cav-3 mRNA and pro-COX-2 Binds to Caveolin-3 in Rat Chondrocytes 103
tein were decreased by the treatment with Cd.
Co-localization of COX-2 and Cav-3 in the caveolae-
enriched membrane fractions of rat chondrocytes
Fig. 3 shows the results of the Western blot analysis using
the antibodies for COX-2 or Cav-3 on the caveolae-enriched
membrane fractions that were obtained from the sucrose den-
sity gradient centrifugations of the stimulator-treated rat
chondrocytes. The COX-2 protein was observed in the frac-
tions numbered 4 and 5. These membrane fractions also con-
tained Cav-3 protein (Fig. 3). 
Co-precipitation of COX-2 with Cav-3 in the Cd- treated
rat chondrocytes
To determine whether there is a direct binding between
the COX-2 and Cav-3 in the detergent-resistant membrane
fractions, lysates of the rat chondrocytes were stimulated with
Cd (5  M for 6 hr), and the purified GST fusion proteins
were initially immuno-precipitated with the antibodies direct-
ed against COX-2 or Cav-3. Subsequently, the precipitates
were electrophoresed by SDS-PAGE and the separated pro-
teins were transferred to a membrane. The formation of a
complex between the COX-2 and Cav-3 was analyzed by
performing Western blot analysis with using the designated
antibodies. The COX-2 or Cav-3 proteins did not precipi-
tate with the control IgG (Fig. 4A, B, designated none). As
shown in Fig. 4, the presence of the COX-2 and Cav-3 com-
plex (Fig. 4A) was detected upon precipitation with COX-
2 antibody. The presence of the COX-2 and Cav-3 com-
plexes could also be detected following precipitation with
the Cav-3 antibody (Fig. 4B). The purified GST fusion pro-
teins also formed complexes with each other without form-
Fig. 1. Morphology and characterization of primarily cultured rat chondrocytes. (A) Light microscopy of confluently grown chondrocytes.
(B) Messenger RNA expression of type II collagen and aggrecan in the cultured rat chondrocytes. Total RNA (500 ng) isolated from rat
chondrocytes was reverse transcribed and polymerase chain reaction was performed (35 cycles). PCR products were separated using
1% agarose gel and stained with ethidium bromide. (C) Isolated membrane protein (30  g/lane) was separated by electrophoresis and
presence of each type II collagen and aggrecan was detected with respective type II collagen and aggrecan antibodies. Data was shown
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Fig. 3. Western blot analysis of COX-2 and Cav-3 in caveolae-rich
membrane fraction. Fractions numbered 4 and 5 are the detergent
resistant caveolae-rich fractions obtained by sucrose density gra-
dient centrifugations and the fractions numbered 9 to 12 are the
detergent soluble membrane fractions. Fractions obtained from
sucrose density gradient centrifugation of detergent solubilized
rat chondrocytes were subjected to Western blot analysis with
respective antibodies. The result was revealed from 2 separate
experiments.
Fig. 2. Expression of COX-2 and Cav-3 mRNA and protein in pri-
marily cultured rat chondrocytes. Cells were changed with medi-
um containing 0.5% FBS in order to exclude serum effect prior to
12 hr of Cd treatment. Then, cells were treated with 5  M of CdCl2
for 6 hr. After treatment, cells were collected with Tri Reagent for
RT-PCR and with lysis buffer for Western blot analysis. The con-
ditions of RT-PCR and Western blotting were same as those of
Fig. 1. The COX-2 and Cav-3 antibodies (in Box). Data was shown
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ing a complex with the immunoprecipitates of the control
IgG (data not shown). This result is consistent with their
co-localization (Fig. 3), as well as the direct binding between
COX-2 and Cav-3 in the caveolae-enriched membrane frac-
tions.
Confocal and electron Microscopy to determine the local-
ization of COX-2 and Cav-3
To confirm the localization of COX-2 and Cav-3 in the
rat chondrocytes treated with Cd (5  M for 6 hr), the cells
were observed with confocal and electron microscopes by
separately staining with the respective antibodies of COX-2
and Cav-3 and with using fluorescence- or gold particle-con-
jugated secondary antibodies. The confocal microscopic results
showed that the immuno-reactivity of COX-2 was detected
in the cytoplasm and plasma membrane (Fig. 5A-b), and the
immuno-reactivity of Cav-3 was detected at the plasma mem-
brane of the cultured chondrocytes (Fig. 5A-a). The merged
image (orange color) showed that at least some portion of
COX-2 and Cav-3 were co-localized in the plasma membrane
(Fig. 5A-c). No single effects of secondary antibodies were
detected (Fig. 5A-d, e). The 15-nm gold particles for COX-
2 were observed in all portions of the cells containing the
caveolae structures. In contrast, the 10-nm gold particles for
Cav-3 were observed only on the surface- or intracellular-
caveolae structures (Fig. 5B). 
DISCUSSION
The results obtained in the present study demonstrate for
the first time that some portion of the COX-2 protein is
bound to Cav-3 protein and the bound complex is co-local-
ized in the caveolae-enriched plasma membrane fractions of
the primarily cultured rat chondrocytes. Several lines of evi-
dences that were provided in the current study support this
conclusion: 1) Western blot analysis of COX-2 indicated that
it is present in the caveolae-enriched membrane fraction along
with Cav-3, 2) the cross-over immuno-precipitation results
show that the COX-2 protein formed a bound complex with
the Cav-3 protein, and 3) with using confocal and electron
microscopes, the immunocytochemistry images show that
Fig. 4. Complex formation between COX-2 and Cav-3 in the rat chondrocytes. Cell lysates and purified GST fusion proteins (incubated for
2 hr at 37 ° C were immunoprecipitated initially with antibodies of COX-2 or Cav-3 and the respective immunoprecipitated (IP) proteins (15
g) were loaded onto each lane of a 10% SDS-polyacrylamide gel. After separation of the proteins by electrophoresis and transferring
the separated proteins to a membrane, the membrane was immunoblotted (IB) using the indicated respective antibodies. Cell lysates
were immunoprecipitated initially with COX-2 antibody (A) or Cav-3 antibody (B). The immunoprecipitational result for GST fusion proteins













Fig. 5. Confocal and electron microscopy of rat chondrocytes im-
muno-cytochemically stained with COX-2 and caveolin antibodies.
Cells were double stained with fluorescein isothiocyanate- and
Texas Red-conjugated secondary antibodies after an initial treat-
ment with either Cav-3 or COX-2 antibodies separately and then
examined under a confocal microscope at their respective wave-
lengths. For each experiment, a least 50 cells were examined and
the presented images represent typical staining pattern for the
majority of examined cells. a, Cav-3; b, COX-2; c, merged image
of a and b; d and e; stained only with secondary antibodies without
the prior treatment of either Cav-3 or COX-2 antibodies (A). Cells
were double stained with different size of gold particle-conjugated
secondary antibodies after an initial treatment with either Cav-3 or
COX-2 antibodies separately and then examined under an elec-
tron microscope. Arrow showed structure of caveolae. # and *
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at least some portion of the COX-2 is co-localized with Cav-
3 in the plasma membrane.
Articular joint degradation is a common feature of rheuma-
toid arthritis and osteoarthritis. Prostaglandins (PG) are impor-
tant regulatory factors in normal cartilage metabolism and
in the pathogenesis of osteoarthritis (OA) and inflammatory
disorders (16, 17). The cyclooxygenase-2 dependent PGE2
was found to be the most abundant PG in the synovial fluid
of rheumatoid arthritis and OA patients, and it has been de-
monstrated to mediate joint inflammation and the degrada-
tion of the cartilage matrix components (17-19). It is inter-
esting that an alternative set of PGs, namely PGD2 and its
metabolites, was recently proposed to have anti-inflamma-
tory properties (20), and to act as a negative feedback loop
for joint inflammation and cartilage catabolism (21). These
observations increased the scientific interest in the possible
differential effects of PGs on chondrogenesis with its poten-
tial implications for the treatment of cartilage pathologies.
Chondrocytes are differentiated from mesenchymal cells
during the embryo’s development (22, 23). The phenotypes
of differentiated chondrocytes in articular cartilage are char-
acterized by the synthesis and maintenance of cartilage-spe-
cific extracellular matrix molecules, including type II colla-
gen and the proteoglycans such as aggrecan. As shown in
Fig. 1, the chondrocytes used in the current study well exp-
ressed type II collagen and aggrecan at the mRNA and pro-
tein levels.
Caveolae were originally described in the endothelial cells
as flask-shaped vesicular invaginations in the plasma mem-
brane, and they are rich in cholesterol, glycosphingolipids
and sphingomyelin, and then are not solubilized by deter-
gents. The membrane receptor associated signaling molecules
(like the G-protein and the Src family kinases) or the mem-
branous enzymes (such as endothelial nitric oxide synthase,
heme oxygenase and cyclooxygenases) are anchored to the
caveolae via the caveolins and the caveolae are implicated to
function as the portals of signal transduction and the vesicu-
lar transport processes (24, 25). These membrane-associated
signaling molecules are known to contain a common amino
acid sequence motif (i.e.,  X XXXX or  XXXX XX ,
in which  designates aromatic amino acids like Trp (W),
Phe (F) or Tyr (Y) and X can be any amino acids) that rec-
ognizes the scaffolding domains that are present in the cave-
olins. Our Western blot analysis results for the caveolae-rich
membrane fraction and the formation of immuno-precipi-
tates by the respective antibodies strongly suggest that there
might be protein-protein interaction between COX-2 and
Cav-3.
COX-2 is a membrane-bound hemoglycoprotein that is
mainly found in the endoplasmic reticulum. As the confocal
and electron microscopy results have shown, most of the
COX-2 is distributed in the intracellular portion (Fig. 5).
However, some portion of the COX-2 is located in the plas-
ma membrane in association with the caveolins. Caveolins
are a family of integral membrane proteins that are contained
in the caveolae. The caveolin family consists of Cav-1, Cav-2
and Cav-3 (26, 27). Normally, Cav-1 and Cav-2 are co-exp-
ressed and they form a hetero-oligomeric complex in many
cell types (28, 29), but Cav-3 is known to be specific for mus-
cle cells (30). With respect to the tissue distribution of Cav-
3, there have been two current investigations that have demon-
strated the expression of Cav-3 in other tissues. One of these
is the brain astroglial cells and the other is the chondrocytes
(11, 12). An unexpected interesting result from the current
study was the expressional change of Cav-3. Except for very
rare cases, the caveolin expression was not changed. Further
study on the changes of Cav-3, according to Cd treatment,
will be necessary.
For the molecular aspect of the protein-protein interaction
between COX and the caveolins, Liou and co-workers have
reported that COX-2 was co-localized and interacted with
caveolin-1 (9). Our unpublished data showed that some por-
tion of COX-2 was also co-localized in the plasma membrane
to form a complex with Cav-2. In addition to COX-2, we
have reported that COX-1 was also co-localized and inter-
acted with Cav-1 and/or Cav-2. This suggests that caveolins
have some regulatory effect on the functions of COX.
The COX system is known to be a microsomal enzyme
system that is mainly located in the endoplasmic reticulum.
The reasons for this un-expected co-localization of COX-2
in the caveolae by its binding to Cav-3 are not clear. One
possibility is the regulation of COX-2 retention in the endo-
plasmic reticulum by a post-translational mechanism, and
this idea needs further study. Further investigations on the
regulatory characteristics of the caveolins in cells, such as the
sorting mechanism of COX-2 to the caveolae, and on the
difference between the microsomal and plasma membranous
COX activity, as well as the changes of microsomal COX
activity upon binding to exogenously added caveolins, may
provide us with some important clues to the physiology and
pathology of COX-2. In addition, it is necessary to clarify the
mechanism of the regulatory effect of Cav-3 on COX-2.
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